Background
==========

Angiotensin receptor blockers (ARBs) are highly effective at reducing blood pressure in patients with arterial hypertension and have shown to protect against end-organ damage. Candesartan cilexetil is an ARB that has been shown to provide effective blood pressure reduction alone[@b1-vhrm-7-085]--[@b4-vhrm-7-085] or in combination with hydrochlorothiazide (HCTZ).[@b5-vhrm-7-085]--[@b7-vhrm-7-085] Its particular benefit, however, is related not only to its blood pressure-lowering effect but more to its protective effect on end-organs such as the heart,[@b8-vhrm-7-085]--[@b11-vhrm-7-085] kidneys,[@b12-vhrm-7-085]--[@b16-vhrm-7-085] and brain.[@b17-vhrm-7-085],[@b18-vhrm-7-085] This has usually been achieved in doses up to 32 mg of candesartan cilexetil and is thought to be mediated by effects beyond blood pressure control.[@b19-vhrm-7-085]

ARBs, including candesartan cilexetil, are frequently used as first-line monotherapy because of their high efficacy, tolerability, and patient compliance. ARB treatment is also an option in patients previously receiving antihypertensive monotherapy with angiotensin-converting enzyme (ACE) inhibitors, β-blockers, or calcium channel blockers, because patients can be safely switched, which results in additional blood pressure lowering.[@b20-vhrm-7-085] When blood pressure control at low ARB doses is not sufficient, either ARB doses may be increased or combination therapy initiated early.[@b21-vhrm-7-085] There is, however, no recommendation on the decision to either combine or increase dose, and reports on clinical experience from primary care are sparse.

We therefore designed a noninterventional study in primary care practice asking physicians to document patients at increased cardiovascular risk who had either been prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12.5 mg or a high-dose monotherapy with candesartan 32 mg because blood pressure control under previous antihypertensive pharmacotherapy was insufficient. We chose a noninterventional design to cover the broadest possible patient spectrum and because results of these studies are directly applicable to clinical practice because of the high external validity of this study type.

Patients and methods
====================

CHILI Triple T was a noninterventional, noncontrolled, open-label study with a 12-week follow-up that was conducted with primary care physicians, internists, or diabetologists throughout Germany. The study was registered at the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) and Kassenärztliche Bundesvereinigung (KBV) in accordance with paragraph 67, section 6 of the German Drug Act 2010. Applicable data protection regulations were respected. Participating physicians received remuneration for the documentation of patients in accordance with the Gebührenordnung für Ärzte (GOÄ). Ethical approval was obtained prior to commencement of the study by the Landesärztekammer Thüringen, Jena, Germany, on August 12, 2008. Written informed consent was obtained from all patients.

Patients
--------

Patients aged at least 18 years were eligible for inclusion when a treatment decision to start candesartan 16 mg and HCTZ 12.5 mg or candesartan 32 mg due to arterial hypertension had been made. Further necessary inclusion criteria were uncontrolled blood pressure (≥130/80 mm Hg) on prior antihypertensive therapy for at least 8 weeks, the presence of additional cardiovascular risk factors (eg, diabetes or hyperlipidemia), and compliance with the prescribing information of Blopress^®^ 16 mg Plus or Blopress^®^ 32 mg (both Takeda Pharma GmbH, Aachen, Germany). Physicians were allowed to adjust the dose of any concomitant medication as necessary.

Objective
---------

The objective of this study was to compare the efficacy and safety of a fixed-dose combination treatment strategy (candesartan cilexetil 16 mg and HCTZ 12.5 mg) with high-dose monotherapy (candesartan cilexetil 32 mg). Treatment strategies were to be compared with respect to blood pressure target achievement and blood pressure achievement in patients with different cardiovascular risks at baseline, and to collect data on tolerability and drug safety in the respective treatment group.

Variables
---------

Three visits were scheduled throughout a 12-week follow-up. At the first visit (enrolment), demographic data, body mass index (BMI), cardiovascular risk factors, concomitant disease conditions, previous or concomitant therapies, and a number of laboratory values were documented. At the mandatory second visit, blood pressure readings, blood glucose, antihypertensive pharmacotherapy, and adverse events were documented. At the end of the observation, blood pressure, antihypertensive treatment, and changes in laboratory values were documented. Blood pressure measurements were conducted in agreement with current guidelines after 5 minutes of rest. Treatment satisfaction was monitored as the proportion of physicians indicating patients reaching blood pressure goal and patients' compliance with treatment.

Statistics
----------

The case report forms were collected by the clinical research organization Immedis GmbH, Königswinter, Germany. Case report forms were checked for consistency and a subset of case report forms verified with the source data (8%). Regarding safety, the trial was adequately sized (n = 4600) to identify rare adverse events, ie, those that may not have been detected in previous clinical studies (incidence 1:1000) with a probability of \>95%. The statistical analysis was performed descriptively and was interpreted in an explorative way. Comparisons were made for a number of variables and analyzed using descriptive statistics. The number of patients is given for each value, and differences were calculated in patients with values at baseline and follow-up (per protocol). Data were analyzed with SPSS for Windows, Version 17.02 (SPSS, Inc., Chicago, IL, USA). The tests applied are indicated in the legends of the tables and figures in this article.

Results
=======

Between October 2008 and February 2009 a total of 4600 patients was included (safety population), of which 4527 were analyzed for efficacy. Patients were stratified into two groups according to treatment chosen: 3337 patients received candesartan cilexetil 16 mg in a fixed-dose combination with 12.5 mg HCTZ (combination therapy group), and 1263 patients received candesartan cilexetil 32 mg (monotherapy group).

Patient and clinical characteristics at baseline
------------------------------------------------

Patients had an overall mean age of 63.1 ± 11.0 years, 44.7% were female, and the mean blood pressure at baseline was 160.8 ± 13.7/94.6 ± 8.3 mm Hg (office measurements). Although age and gender were comparable between groups, there was a statistically significant difference with respect to a slightly higher systolic blood pressure at baseline, more prior revascularization procedures, renal insufficiency, diabetic nephropathy, peripheral arterial disease, ankle brachial index \< 0.9, and pulse wave velocity \> 12 m/s in patients receiving candesartan cilexetil 32 mg ([Table 1](#t1-vhrm-7-085){ref-type="table"}).

Pharmacotherapy at baseline and during follow-up is illustrated in [Table 2](#t2-vhrm-7-085){ref-type="table"}. β-blockers, ACE inhibitors, and calcium channel blockers were the most frequently used drugs at baseline. Either candesartan cilexetil in mono- or combination therapy was added to an existing regimen or prior medication was substituted, resulting in 100% coverage at baseline. Concomitant drug use was low and comparable except for a nominally more frequent use of diuretics in the monotherapy group (8.2% vs 2.7%; *P* \< 0.001).

Blood pressure reduction
------------------------

At baseline, patients had comparable blood pressure values in both treatment arms and in subgroups, defined by the presence of hypertension grade 1--3 ([Figure 1](#f1-vhrm-7-085){ref-type="fig"}). The use of combination therapy resulted in a blood pressure reduction of −28.5 ± 13.8/−14.2 ± 9.4 mm Hg (*P* \< 0.001 with blood pressure of 160.2 ± 13.3/94.5 ± 8.2 mm Hg at baseline). The use of high-dose monotherapy reduced blood pressure by −29.73 ± 15.3/−14.1 ± 9.6 mm Hg (*P* \< 0.001 with blood pressure of 162.4 ± 14.7/94.7 ± 8.7 mm Hg at baseline). Differences were highly significant compared with baseline (*P* \< 0.0001) and significant for the difference between systolic blood pressure values (*P* = 0.011). Target blood pressure achievement (\<140/90 mm Hg) was 74.3% in the combination therapy group and 70.2% in the monotherapy group.

The treatment-induced blood pressure reduction for patient groups, defined by the presence of hypertension grade 1--3 (see mean blood pressure readings at baseline in the respective subgroups), is illustrated in [Figure 1](#f1-vhrm-7-085){ref-type="fig"}. Blood pressure reduction was moderate in grade 1 hypertension (−24.1/−12.6 mm Hg combination vs −24.6/−12.5 mm Hg monotherapy; both *P* \< 0.0001 vs baseline), increased in grade 2 hypertension (−31.2/−15.2 vs −31.4/−14.3; both *P* \< 0.0001 vs baseline), and was strongest in patients with grade 3 hypertension (−46.6/−21.3 vs −46.5 vs −20.3; both *P* \< 0.0001 vs baseline). The correlation (Pearson 0.754) between blood pressure at baseline and blood pressure reduction was highly significant (*P* \< 0.001); differences between mono- and combination therapy were not observed (*P* = n.s.).

Both patient groups had mostly either high or very high added risk at baseline, defined by blood pressure readings and the presence of comorbid risk factors and disease as outlined in the European Society of Hypertension (ESH)/European Society of Cardiology (ESC) guidelines ([Figure 2](#f2-vhrm-7-085){ref-type="fig"}, panel A and B).[@b21-vhrm-7-085] This applied to 44.9% (high) and 52.9% (very high) of patients with the fixed-dose combination, and to 37.8% (high) and 59.7% (very high) in the high-dose monotherapy group. Risk was substantially reduced at the 12-week follow-up (*P* \< 0.001 vs baseline in both groups); substantially fewer patients had high or very high added risk, and more patients had low or moderate added risk. Differences between both treatment groups were negligible.

Blood pressure in patient subgroups
-----------------------------------

The blood pressure reduction in subgroups of patients defined by prior or concomitant antihypertensive pharmacotherapy is displayed in [Table 3](#t3-vhrm-7-085){ref-type="table"}. Differences compared with baseline were significant (*P* \< 0.001), with the least effect observed in patients with prior ARB therapy and those with concomitant use of ACE inhibitors. Pronounced effects were observed in patients with prior β-blocker or diuretic therapy. Differences between mono- and dual-combination therapy in the respective subgroups were generally in favor of high-dose monotherapy but were significant only for patients for whom a β-blocker was withdrawn (*P* = 0.006).

Blood pressure reductions were further investigated in subgroups of patients defined by age, gender, and BMI ([Figure 3](#f3-vhrm-7-085){ref-type="fig"}; two panels first row), dyslipidemia, waist circumference, and smoking ([Figure 3](#f3-vhrm-7-085){ref-type="fig"}; two panels second row), and prior cardiovascular event, glomerular filtration rate, and the presence of microalbuminuria ([Figure 3](#f3-vhrm-7-085){ref-type="fig"}; two panels last row). Differences were significant for patients aged ≤65 years, patients with BMI ≥ 30 kg/m^2^, patients with dyslipidemia, and those who smoke (*P* \< 0.05).

Metabolic parameters and tolerability
-------------------------------------

Twelve weeks after candesartan cilexetil/HCTZ initiation, laboratory values such as glycated hemoglobin, fasting and postprandial glucose, lipids, and renal parameters generally improved, irrespective of whether mono- or combination therapy was employed ([Table 4](#t4-vhrm-7-085){ref-type="table"}). Differences between treatments were, however, nonsignificant. During the course of the observation, 28 adverse events were reported in patients receiving a fixed-combination treatment (n = 28/3337; 0.8%) and 15 in the monotherapy treatment group (n = 15/1263; 1.2%). One event in each group was considered to be serious. Most adverse events were related to cardiac or vascular disorders. Details are displayed in [Table 5](#t5-vhrm-7-085){ref-type="table"} (MedDRA^®^ Primary System Organ Classes, Northrop Grummon Corporation, California, US).

Discussion
==========

Awareness that the majority of patients require two or more antihypertensive agents to reach their blood pressure goal led to the therapeutic concept to introduce combination treatment early, which usually comprises a thiazide diuretic.[@b21-vhrm-7-085],[@b22-vhrm-7-085] On the other hand, clinical study evidence also suggests that sustainable inhibition of the renin--angiotensin--aldosterone system (RAAS) at the tissue level, as provided by high-dose monotherapy with an ARB, might afford improved cardiovascular protection beyond pure blood pressure reduction.[@b19-vhrm-7-085] There is, however, no recommendation on this decision to either combine or increase dose, and reports on clinical experience from primary care are sparse. Therefore, we designed a noninterventional study, the key findings of which are as follows. First, the fixed-dose combination of candesartan cilexetil 16 mg and HCTZ 12.5 mg and high-dose monotherapy with candesartan 32 mg was almost equally effective at lowering blood pressure in patients at increased cardiovascular risk. Blood pressure reduction was enhanced with higher baseline blood pressure. Differences were small in subgroups defined by patients' characteristics, risk factors, and end-organ disease. Second, the degree of added cardiovascular risk, as outlined by the ESH/ESC guidelines,[@b21-vhrm-7-085],[@b23-vhrm-7-085] was substantially reduced in both treatment groups. Third, tolerability was high, with 0.8% of patients experiencing adverse events in the fixed-combination and 1.2% in the high-dose monotherapy group. Fourth, physicians chose to use high-dose monotherapy in patients with more advanced disease.

Blood pressure reduction in CHILI Triple T in perspective
---------------------------------------------------------

Clinical trials evaluating candesartan monotherapy or candesartan/HCTZ combination therapy consistently show safe and effective blood pressure reduction.[@b7-vhrm-7-085],[@b24-vhrm-7-085]--[@b29-vhrm-7-085] Furthermore, there is evidence from a study published by Ohma et al that the ARB candesartan is more effective compared with the first-generation ARB losartan. The reduction in blood pressure and the proportion of patients with normalized blood pressure were greater with the candesartan 16 mg and HCT 12.5 mg combination than with the losartan 50 mg and HCT 12.5 mg combination,[@b30-vhrm-7-085] supporting the interpretation that not all ARBs are similarly effective. The antihypertensive effect of candesartan and HCT has been shown to be dose related over a wide range of doses, and the effects of the components are fully additive.[@b31-vhrm-7-085] The present study comparing high-dose candesartan 32 mg monotherapy with candesartan and HCTZ combination therapy revealed similar effective blood pressure reduction of both treatment regimens ([Figure 1](#f1-vhrm-7-085){ref-type="fig"}) independent of the baseline risk stratification ([Figure 2](#f2-vhrm-7-085){ref-type="fig"}). A higher baseline risk (which corresponds to a higher blood pressure at baseline) consistently resulted in a more pronounced blood pressure reduction of the respective treatment regimen. These results support the use of both treatment regimens for hypertensive patients, spanning the complete risk spectrum of hypertension-induced complications independent of risk at baseline.

High-dose monotherapy versus dual-combination treatment
-------------------------------------------------------

Based on the results of the present study, both treatment regimens were similarly effective at reducing blood pressure. Systolic blood pressure reduction was slightly more pronounced in the high-dose monotherapy group, but this difference disappeared when grouping patients according to baseline grade of hypertension ([Figure 1](#f1-vhrm-7-085){ref-type="fig"}).

The rationale for combining an ARB with HCTZ is that the mechanism of action is complementary and RAAS blockade augments the blood pressure-lowering efficacy of diuretics while alleviating their adverse effects. Thiazide diuretics lower blood pressure through natriuresis, resulting in volume depletion and reduction of peripheral vascular resistance over time.[@b32-vhrm-7-085],[@b33-vhrm-7-085] Combining an ARB with a diuretic reduces vasoconstriction mediated by angiotensin II, at the same time reducing volume and enhancing the efficacy of both antihypertensive components. Therefore, combination therapy may help patients attain blood pressure control in a timelier manner. To achieve this, ARBs at a standard dose are usually combined with low-dose diuretics.[@b34-vhrm-7-085] The rationale to use high-dose ARBs is their proven protective effect for end-organs. Their particular benefit relates to their protective effect on end-organs such as the heart,[@b8-vhrm-7-085]--[@b11-vhrm-7-085] kidneys,[@b12-vhrm-7-085]--[@b16-vhrm-7-085] and brain.[@b17-vhrm-7-085],[@b18-vhrm-7-085] However, results were usually obtained with high doses of candesartan cilexetil, such as 32 mg or even higher, as applied in the SMART (Supra Maximal Atacand Renal Trial).[@b34-vhrm-7-085] An advantage of including a high-dose ARB in antihypertensive treatment is the low rate of adverse events associated with this class compared with other antihypertensive agents.[@b35-vhrm-7-085],[@b36-vhrm-7-085] Both ARB and HCTZ combination and ARB monotherapy have been shown to be associated with a low rate of treatment discontinuations.[@b37-vhrm-7-085] Taking into account these considerations, a further rational approach would be to make use of the end-organ protective effect using 32 mg of an ARB and combining this dose with HCTZ as outlined previously. This has been shown to be effective in clinical trials, and further clinical practice research is ongoing.[@b29-vhrm-7-085] We were able to show that younger people aged ≤ 65 years, patients with dyslipidemia, smokers, patients with a prior cardiovascular event, and patients with microalbuminuria had improved blood pressure reduction in the high-dose candesartan mono-therapy group compared with patients without the respective condition. Physicians were also more likely to assign high-dose monotherapy to patients with pre-existing (vascular) disease. These findings are in accordance with observations showing that the use of an ARB reduces both proteinuria and the rate of deterioration of renal function beyond those seen with equivalent blood pressure reduction from conventional antihypertensive agents.[@b12-vhrm-7-085]--[@b16-vhrm-7-085] In particular, proteinuria has been a marker of kidney disease, and recent research has shown that renal and cardiovascular outcomes seem to correlate with the pretreatment levels of proteinuria and with the reduction of proteinuria with treatment.[@b38-vhrm-7-085]--[@b42-vhrm-7-085] In the present trial, patients on candesartan experienced higher reductions in microalbuminuria in the candesartan high-dose arm compared with the candesartan and HCTZ combination treatment arm, although this change did not reach statistical significance. However, patients with prior microalbuminuria responded to candesartan with increased blood pressure reduction, which might reflect organ-protective effects of high-dose RAAS blockade.

Classification of cardiovascular risk and impact of candesartan cilexetil treatment
-----------------------------------------------------------------------------------

The ESH/ESC guidelines recommend total cardiovascular risk evaluation in every patient in order to refine pharmacotherapy. The blood pressure threshold at which to commence drug administration, the target blood pressure to be reached by drug treatment, and the decision to use two-drug combinations as an initial treatment step are influenced by this classification.[@b43-vhrm-7-085] The 2009 update of this guideline now underlines that the presence of subclinical organ damage results in cardiovascular risk to be in the high range, ie, an absolute risk of at least 20 cardiovascular events in 100 patients within 10 years.[@b44-vhrm-7-085] The update further expresses that there is indisputable evidence that major drug classes differ in their ability to protect against overall cardiovascular risk or cause-specific cardiovascular events such as stroke and myocardial infarction.[@b44-vhrm-7-085]

We were able to demonstrate with this noninterventional study that added cardiovascular risk is substantially lowered with either high-dose mono- or combination therapy including candesartan cilexetil. Although several two-drug combinations are suitable for clinical use, outcome trials point to a favorable role of combining RAAS blocking agents with diuretics.[@b45-vhrm-7-085] Further, there is a particular role for ARBs, eg, candesartan cilexetil, in patients with diabetes.[@b44-vhrm-7-085]

Limitations
-----------

The present results have to be considered against the background of potential limitations. The study was not controlled, and therefore the role of a placebo effect or the withdrawal of antihypertensive agents is unknown. Second, in the absence of a randomization procedure, the influence of unknown biases, eg, through patient selection, cannot be ruled out. Thus, we observed more patients with higher risk and more concomitant diseases in the monotherapy group. This selection clearly indicates that physicians preferred monotherapy in the group with higher risk and avoided diuretic impairment. Concomitant diuretic prescription could be due to a higher rate of kidney disease. Third, changes in concomitant medication influencing the metabolic profile (eg, lipid-lowering drugs, oral antidiabetic agents, or insulin) have not been documented in the present study. However, it should be kept in mind that observational studies in primary care, including typical patient groups and reflecting current treatment approaches, are useful for complementing the findings of randomized controlled trials.[@b46-vhrm-7-085]

Conclusion
==========

Both the fixed-dose combination of candesartan cilexetil 16 mg and HCTZ 12.5 mg and high-dose monotherapy with candesartan 32 mg are highly effective and safe for lowering blood pressure in patients at increased cardiovascular risk with mild, moderate, or severe hypertension. The choice of either strategy therefore largely depends on the principal aim: blood pressure reduction with pronounced volume restriction or pronounced additional end-organ protection.
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![Blood pressure reduction overall and subgroups with grade 1--3 hypertension (HT) 12 weeks after either candesartan cilexetil/hydrochlorothiazide combination (treatment arm 1) or high-dose candesartan monotherapy 32 mg (treatment arm 2). Blood pressure lowering in the total and the subgroups defined by the presence of grade 1, 2, or 3 hypertension was significant (*P* \< 0.001, pairwise comparison).](vhrm-7-085f1){#f1-vhrm-7-085}

![Cardiovascular risk (%) at baseline and after follow-up according to the European Society of Hypertension/European Society of Cardiology 2007 guidelines.[@b21-vhrm-7-085] **Upper panel:** patients receiving candesartan/hydrochlorothiazide; **Lower panel:** patients receiving candesartan 32 mg. Stratification of cardiovascular risk in five categories. Low, moderate, high, and very high added risk refers to 10-year risk of a cardiovascular fatal or nonfatal event.](vhrm-7-085f2){#f2-vhrm-7-085}

![Systolic blood pressure reduction patient characteristic (age, gender, and BMI: two panels first row), concomitant risk factors (hyperlipidemia, waist circumference, smoking: two panels second row), and end-organ damage (prior CV event, GFR, and MAU: two panels last row).\
**Notes:** \*Significant differences are indicated (*P*-value). Other comparisons are not significant.\
**Abbreviations:** BMI, body mass index; CV, cardiovascular; GFR, glomerular filtration rate; HCTZ, hydrochlorothiazide; MAU, microalbuminuria.](vhrm-7-085f3){#f3-vhrm-7-085}

###### 

Baseline characteristics of the study population (U1)

  **Variables**                                             **Candesartan 16 mg + hydrochlorothiazide 12.5 mg**   **Candesartan 32 mg**   ***P*-value combination vs monotherapy**                  
  --------------------------------------------------------- ----------------------------------------------------- ----------------------- ------------------------------------------ -------------- ---------
  Males (%)                                                 1828                                                  54.8                    713                                        56.5           0.288
  Age (years)                                               3328                                                  63.3 ± 11.1             1259                                       62.8 ± 10.6    0.156
  Waist circumference (cm)                                  2706                                                  102.5 ± 14.0            1002                                       103.0 ± 15.3   0.388
  Smokers (%)                                               729                                                   21.8                    276                                        21.9           0.953
  Blood pressure office measurement                                                                                                                                                                 
    Systolic (mm Hg)                                        3336                                                  160 ± 13                1260                                       162 ± 15       \<0.001
    Diastolic (mm Hg)                                       3337                                                  94 ± 8                  1259                                       95 ± 9         0.374
  Diabetes (%)                                              240                                                   7.2                     92                                         7.3            0.792
  Concomitant disease (%)                                                                                                                                                                           
    Coronary artery disease                                 1296                                                  38.8                    505                                        40.0           0.387
    Myocardial infarction                                   399                                                   12.0                    176                                        13.9           0.065
    Angina pectoris                                         753                                                   22.6                    309                                        24.5           0.151
    Prior revascularization                                 450                                                   13.5                    203                                        16.1           0.018
    Heart failure                                           700                                                   21.0                    278                                        22.0           0.415
    Stroke                                                  167                                                   5.0                     63                                         5.0            0.985
    Renal insufficiency                                     268                                                   8.0                     152                                        12.0           \<0.001
    Diabetic nephropathy                                    259                                                   7.8                     136                                        10.8           0.001
    Diabetic retinopathy                                    235                                                   7.0                     98                                         7.8            0.402
    Peripheral artery disease                               406                                                   12.2                    187                                        14.8           0.018
    Prior cardiovascular disease in first-grade relatives   1944                                                  58.3                    731                                        57.9           0.868
    IMT \> 0.9 mm or plaque                                 505                                                   70.5                    235                                        69.7           0.083
    ABI \< 0.9                                              212                                                   29.6                    131                                        38.9           \<0.001
  PWV \> 12 ms                                              65                                                    9.1                     55                                         16.3           \<0.001

**Abbreviations:** ABI, ankle brachial index; IMT, intima media thickness; PWV, pulse wave velocity; SD, standard deviation.

###### 

Pharmacotherapy for the treatment of hypertension at baseline (% of patients)

                                                                               **Candesartan 16 mg + hydrochlorothiazide 12.5 mg**   **Candesartan 32 mg**   ***P*-value combination vs monotherapy**           
  ---------------------------------------------------------------------------- ----------------------------------------------------- ----------------------- ------------------------------------------ ------- ---------
  Baseline                                                                                                                                                                                                      
    Any (of the 5 groups below)                                                5264                                                  95.8                    2206                                       95.0    0.113
    Angiotensin-converting enzyme inhibitors                                   1613                                                  29.4                    642                                        27.7    0.128
    Angiotensin receptor blockers                                              425                                                   7.7                     217                                        9.3     0.018
    β-blockers                                                                 1561                                                  28.4                    636                                        27.4    0.359
    Calcium channel blockers                                                   1049                                                  19.1                    424                                        18.3    0.390
    Diuretics                                                                  616                                                   11.2                    287                                        12.4    0.147
  Candesartan 16 mg/hydrochlorothiazide 12.5 mg                                5492                                                  100.0                   n.a.                                       n.a.    n.a.
  Candesartan 32 mg                                                            n.a.                                                  n.a.                    2321                                       100.0   n.a.
  Concomitant pharmacotherapy                                                                                                                                                                                   
    Any (of the 5 groups below)                                                659                                                   13.4                    435                                        20.3    \<0.001
    Angiotensin-converting enzyme inhibitors                                   35                                                    0.7                     35                                         1.6     0.001
    Angiotensin receptor blockers[\*](#tfn3-vhrm-7-085){ref-type="table-fn"}   46                                                    0.9                     18                                         0.8     0.706
    β-blockers                                                                 235                                                   4.8                     102                                        4.8     0.996
    Calcium channel blockers                                                   210                                                   4.3                     105                                        4.9     0.228
    Diuretics[\*](#tfn3-vhrm-7-085){ref-type="table-fn"}                       133                                                   2.7                     175                                        8.2     \<0.001

**Note:**

Other than candesartan 32 mg or candesartan 16 mg and hydrochlorothiazide12.5 mg.

###### 

Blood pressure reduction versus baseline with respect to prior and concomitant pharmacotherapy for the treatment of hypertension

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                               **Candesartan 16 mg + hydrochlorothiazide 12.5 mg**   **Candesartan 32 mg**   ***P*-value**\                                               
                                                                                                                             **Δ combination vs Δ monotherapy**                           
  -------------------------------------------- ----------------------------------------------------- ----------------------- ------------------------------------ ----- ------- --------- -------
  Prior therapy                                                                                                                                                                           

    No change of prior therapy                 905                                                   28.39                   \<0.001                              373   29.57   \<0.001   0.166

    Change of prior therapy                    2395                                                  28.53                   \<0.001                              865   29.78   \<0.001   0.037

  Withdrawn therapy                                                                                                                                                                       

    Angiotensin-converting enzyme inhibitors   1377                                                  28.66                   \<0.001                              494   30.21   \<0.001   0.046

    Angiotensin receptor blockers              391                                                   25.71                   \<0.001                              190   26.20   \<0.001   0.681

    β-blockers                                 327                                                   28.52                   \<0.001                              130   33.06   \<0.001   0.006

    Calcium channel blockers                   342                                                   30.33                   \<0.001                              122   30.34   \<0.001   0.996

    Diuretics                                  427                                                   30.40                   \<0.001                              53    32.96   \<0.001   0.259

  No. of withdrawn drugs                                                                                                                                                                  

    1 drug withdrawn                           1933                                                  28.22                   \<0.001                              745   29.29   \<0.001   0.090

    ≥ 2 drugs withdrawn                        468                                                   29.82                   \<0.001                              121   32.39   \<0.001   0.161

  Concomitant pharmacotherapy                                                                                                                                                             

    Angiotensin-converting enzyme inhibitors   34                                                    27.79                   \<0.001                              34    29.85   \<0.001   0.556

    Angiotensin receptor blockers              9                                                     30.22                   \<0.001                              3     47.67   0.019     0.099

    β-blockers                                 230                                                   30.71                   \<0.001                              95    29.07   \<0.001   0.403

    Calcium channel blockers                   204                                                   30.39                   \<0.001                              95    29.47   \<0.001   0.649

    Diuretics                                  131                                                   29.60                   \<0.001                              150   30.25   \<0.001   0.741

  No. of concomittant drugs                                                                                                                                                               

    No concomitant drugs                       2659                                                  28.27                   \<0.001                              908   29.36   \<0.001   0.049

    1 concomittant drug                        1047                                                  28.65                   \<0.001                              350   30.73   \<0.001   0.020

    ≥ 2 concomittant drugs                     2271                                                  28.42                   \<0.001                              899   29.35   \<0.001   0.113
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Laboratory values at baseline and during follow-up

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                    **Candesartan 16 mg + hydrochlorothiazide 12.5 mg**   **Candesartan 32 mg**   ***P*-value**\                                                                       
                                                                                                                                  **Δ combination vs Δ monotherapy**                                                   
  ------------------------------------------------- ----------------------------------------------------- ----------------------- ------------------------------------ --------------- --------------- --------------- -------
  Blood glucose                                                                                                                                                                                                        

    Fasting blood glucose (mg/dL)                   108.8 ± 28.9                                          103.2 ± 25.8            5.5 ± 18.5                           110.5 ± 32.2    106.3 ± 27.5    4.19 ± 23.26    0.257

    Postprandial glucose (mg/dL)                    147.7 ± 34.9                                          136.6 ± 32.1            11.1 ± 27.1                          148.6 ± 40.3    136.6 ± 37.3    12.0 ± 34.9     0.717

  Lipids                                                                                                                                                                                                               

    Total cholesterol (mg/dL)                       218.2 ± 34.6                                          205.0 ± 34.5            13.3 ± 29.0                          220.4 ± 43.3    210.9 ± 86.7    9.4 ± 86.4      0.351

    High-density lipoprotein cholesterol (mg/dL)    51.1 ± 15.2                                           52.6 ± 16.1             1.50 ± 10.0                          52.4 ± 16.6     53.8 ± 19.5     1.4 ± 16.8      0.883

    Low-density lipoprotein cholesterol (mg/dL)     131.9 ± 34.9                                          121.9 ± 30.2            9.95 ± 25.4                          135.0 ± 43.9    122.7 ± 32.3    12.3 ± 40.6     0.296

    Triglycerides (mg/dL)                           187.0 ± 92.7                                          168.7 ± 71.6            18.3 ± 65.8                          189.1 ± 96.2    173.4 ± 112.6   15.7 ± 109.8    0.650

  Renal parameters                                                                                                                                                                                                     

    Serum-creatinine (mg/dL)                        1.55 ± 7.3                                            1.04 ± 1.5              0.5 ± 7.4                            2.3 ± 10.3      1.1 ± 0.7       1.24 ± 10.3     0.157

    Glomerular filtration rate (mL/min/1.73 m^2^)   71.6 ± 12.2                                           73.5 ± 22.7             1.90 ± 12.17                         64.8 ± 21.4     67.4 ± 22.4     2.6 ± 13.9      0.664

    Albuminuria (mg/24 h)                           76.5 ± 213.0                                          46.7 ± 87.8             30.7 ± 172.8                         123.6 ± 253.1   84.2 ± 205.8    39.03 ± 133.9   0.666
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Number of patients with adverse events or serious adverse events during the survey and adverse events coded by MedDRA^®^ Version 11.1 (safety population: n = 4600)

                                                           **Candesartan 16 mg hydrochlorothiazide 12.5 mg (n = 3337)**   **Candesartan 32 mg (n = 1263)**          
  -------------------------------------------------------- -------------------------------------------------------------- ---------------------------------- ------ ------
  No adverse events                                        3313                                                           99.3                               1245   98.6
  Any adverse events                                       24                                                             0.7                                18     1.4
    Serious adverse events                                 1                                                              0.0                                2      0.2
    Not serious                                            23                                                             0.7                                16     0.9
  **MedDRA^®^ primary system organ classes**                                                                                                                        
  Adverse events                                           24                                                             100                                18     100
    General disorders and administration site conditions   1                                                              4.2                                1      5.6
    Skin and subcutaneous tissue disorders                 3                                                              12.5                               1      5.6
    Respiratory, thoracic, and mediastinal disorders       4                                                              16.7                               6      33.3
    Gastrointestinal disorders                             3                                                              12.5                               1      5.6
    Nervous system disorders                               2                                                              8.3                                1      5.6
    Vascular disorders                                     5                                                              20.8                               1      5.6
    Cardiac disorders                                      4                                                              16.7                               4      22.2
    Musculoskeletal and connective tissue disorders        1                                                              4.2                                1      5.6
    Investigations                                         1                                                              4.2                                1      5.6
